Access the full text.
Sign up today, get DeepDyve free for 14 days.
Maurie Markman (1996)
Intraperitoneal Therapy of Ovarian Cancer.The oncologist, 1 1 & 2
M. Gore, A. Oza, G. Rustin, J. Malfetano, H. Calvert, D. Clarke‐Pearson, J. Carmichael, G. Ross, R. Beckman, S. Fields (2002)
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer.European journal of cancer, 38 1
S.F. Wen, V. Mahavni, E. Quijano (2001)
Evidence of p53 gene transfer and its biological activities in ovarian cancer patients receiving multiple cycles of recombinant adenovirus expressing wild-type p53 [abstract]Proc Am Soc Clin Oncol, 20
M. Markman, T. Hakes, B. Reichman (1992)
Phase II trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancerJ Cancer Res Clin Oncol, 119
J. Thigpen, J. Blessing, H. Ball, S. Hummel, R. Barrett (1994)
Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 9
M. Markman, A. Kennedy, K. Webster, G. Peterson, B. Kulp, J. Belinson (2000)
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.Gynecologic oncology, 78 3 Pt 1
Daniel Fink, S. Nebel, Stefan Aebi, Hua Zheng, Bruno Cenni, Alissar Nehmé, R. Christen, Stephen Howell (1996)
The role of DNA mismatch repair in platinum drug resistance.Cancer research, 56 21
K. Hatch, J. Beecham, J. Blessing, W. Creasman (1991)
Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A gynecologic oncology group study of second‐line therapy in 105 patientsCancer, 68
B. Lund, O. Hansen, Karen Theilade, Mogens Hansen, J. Neijt (1994)
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.Journal of the National Cancer Institute, 86 20
H. Malmstrom, M. Ridderheim, B. Sorbe (1999)
Salvage treatment of advanced ovarian cancer with hycamtin [abstract]Proc Am Soc Clin Oncol, 18
Maurie Markman, J. Blessing, David Moore, H. Ball, S. Lentz (1998)
Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.Gynecologic oncology, 69 3
P. Stiff, R. Bayer, C. Kerger, R. Potkul, D. Malhotra, D. Peace, D. Smith, S. Fisher (1997)
High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 4
P. Sørensen, M. Høyer, A. Jakobsen, H. Malmström, H. Havsteen, K. Bertelsen (2001)
Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.Gynecologic oncology, 81 1
M. Markman, K. Iseminger, K. Hatch, W. Creasman, W. Barnes, B. Dubeshter (1996)
Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report.Gynecologic oncology, 62 1
M. Seymour, JL Mansi, Cj Gallagher, ME Gore, PG Harper, Trj Evans, PM Edmonds, M. Slevin (1994)
Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.British Journal of Cancer, 69
M. Markman, R. Rothman, T. Hakes, B. Reichman, W. Hoskins, S. Rubin, W. Jones, L. Almadrones, J. Lewis (1991)
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 9 3
D. Alberts, P. Liu, E. Hannigan, R. O'Toole, S. Williams, S. Williams, J. Young, E. Franklin, D. Clarke‐Pearson, V. Malviya, B. Dubeshter, B. Dubeshter, M. Adelson, W. Hoskins (1996)
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.The New England journal of medicine, 335 26
N. Colombo, M. Marzola, G. Parma (1996)
Paclitaxel vs. CAP (cyclophosphamide, adriamycin, cisplatin) in recurrent platinum sensitive ovarian cancer: a randomised phase II study [abstract]Proc Am Soc Clin Oncol, 15
G. Creemers, G. Bolis, M. Gore, G. Scarfone, Á. Lacave, J. Guastalla, R. Despax, G. Favalli, R. Kreinberg, S. Belle, I. Hudson, J. Verweij, W. Huinink (1996)
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 12
A. Einzig, P. Wiernik, J. Sasloff, C. Runowicz, G. Goldberg (1992)
Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 11
G. Rustin, A. Nelstrop, M. Crawford, J. Ledermann, H. Lambert, R. Coleman, J. Johnson, H. Evans, S. Brown, W. Oster (1997)
Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 1
M. Parmar, Torri, A. Bonaventura, C. Bonazzi, N. Colombo, JF Delaloye, S. Marsoni, C. Mangioni, J. Sandercock, C. Sessa, C. Williams, A. Tinazzi, M. Flann, K. Geiser, N. Scorpiglione, J. Stewart, J. Chaves, E. Palmeiro, A. Curtain, T. McCormack, C. Gennatas, F. Marras, TG Oppo, M. Balestrino, C. Malzoni, M. Malzoni, M. Belli, M. Geminiani, G. Crestani, A. Monaco, Vavala, E. Piatto, G. Barattini, P. Fornara, M. Chetri, G. Santeufemia, F. Artioli, D. Carone, G. Fanizza, R. Trentadue, D. Priolo, P. Scollo, Sc Nigro, M. Petrina, P. Mastrantonio, GD Spanna, R. Zagni, C. Belloni, R. Colleoni, L. Redaelli, A. Cavagnini, G. Costanzo, D. Perroni, S. Arienti, G. Orfanotti, F. Cantoni, R. Secli, A. Bianchi, R. Martinello, G. Mollica, D. Maizzi, M. Picchiarelli, G. Fiorini, M. Borsani, E. Colombo, S. Garsia, L. Melgrati, G. Paggi, GM Brunenghi, M. Casini, L. Isa, R. Algeri, G. Prozio, G. Belfiore, F. Angelini, M. D'aprile, M. Moreschi, ML Mauri, N. Natale, FM Senzani, G. Pavanato, G. Poggi, G. Garuti, M. Luerti, G. Cruciani, F. Pagano, M. Baccolo, E. Poddi, L. Bocciolone, Martin Sabelli, R. Maggi, C. Restelli, A. D'Antona, M. Locatelli, A. Pessi, A. Raina, S. Chiari, A. Gabriele, Pittelli, P. Iacobelli, L. Dogliotti, G. Gorzegno, P. Musso, G. Vegna, G. Coco, DG Alletti, F. Picciotto, Lucchese, A. Epis, V. Palumbo, G. Drudi, A. Ravaioli, D. Zampella, M. Morandi, G. Gorga, C. Zucchelli, S. Cariello, L. Galletto, M. Sussio, L. Massacesi, M. Massacesi, A. Carli, E. Tucci, E. Tajani, G. Corrado, S. Bumma, A. Durando, M. Massobrio, M. Sberveglieri, M. Biasio, E. Guercio, R. Jura, S. Danese, T. Wierdis, C. Farnelli, G. Tarantino, R. Grassi, F. Repetti, B. Rocchi, M. Grampa, A. Ercoli, C. Griso, E. Signori, L. Zanini, M. Presti, M. Klimek, K. Urbański, A. Biswas, O. Viegas, O. Kochli, E. Dreher, M. Fey, G. Beck, J. Ludin, H. Bonnefoi, F. Krauer, J. Bauer, G. Delmore, C. Furrer, U. Lorenz, B. Thurlimann, L. Bronz, P. Sanna, D. Wyss, A. Goldhirsch, T. Gyr, L. Leidi, G. Pastorelli, O. Pagani, P. Rey, U. Hailer, J. Benz, S. Kaye, N. Reed, R. Symonds, R. Atkinson, A. Axford, G. Rustin, M. Seckl, Ja Green, Scott, D. Guthrie, P. Harper, F. Calman, H. Dobbs, P. Weir, A. Cassoni, Jacob Lederman, R. Souhami, J. Bozzino, F. Adab, C. Redman, J. Scoble, M. Paterson, F. Daniel, N. Cowley, CJ Williams, D. Spooner, A. Hong, M. Mcillmurray, P. Hendy-Ibbs, Hall, T. Iveson, J. Whitehouse, R. Garry, A. Lamont, A. Robinson, C. Trask, A. Clubb, D. Murrell, G. Newman, M. Wilkins, WO Goldthorp, J.K. Roberts, DJ Radstone, MJ Whipp, J. Ledermann, J. Pater, M. Buyse, G. Omura (1998)
ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancerThe Lancet, 352
W. Huinink, M. Gore, J. Carmichael, A. Gordon, J. Malfetano, I. Hudson, C. Broom, C. Scarabelli, N. Davidson, M. Spanczynski, G. Bolis, H. Malmstrom, R. Coleman, S. Fields, J. Héron (1997)
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 6
D. Slamon, S. Leyland-Jones, S. Shak, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, J. Baselga, L. Norton (1998)
Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial, 17
John Kavanagh, A. Kudelka, C. León, D. Tresukosol, M. Hord, M. Finnegan, E. Kim, D. Varma, A. Forman, Paul Cohen, C. Edwards, R. Freedman, C. Verschraegen (1996)
Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.Clinical cancer research : an official journal of the American Association for Cancer Research, 2 5
M. Gore, I. Fryatt, E. Wiltshaw, T. Dawson (1990)
Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.Gynecologic oncology, 36 2
H. Bruckner, B. Motwani (1989)
Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue.American journal of obstetrics and gynecology, 161 5
J.C. Schink, L.S. Harris, E.R. Grosen (1995)
Altretamine (Hexalen) an effective salvage chemotherapy after paclitaxel (Taxol) in women with recurrent platinum-resistant ovarian cancer [abstract]Proc Am Soc Clin Oncol, 14
G. Aravantinos, D. Skarlos, P. Kosmidis (1994)
Taxol in platinum pretreated ovarian cancer patients (preliminary results)Ann Oncol, 5
MJ Lind, B. Cantwell, MJ Millward, A. Robinson, M. Proctor, D. Simmons, J. Carmichael, AL Harris (1992)
A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.British Journal of Cancer, 65
E. Simonsen, C. Bengtsson, T. Hogberg (1987)
A phase II study of the effect of 4′-epi-doxorubicin, administered in high-dose 150mg in 24 hours intravenous infusion in advanced ovarian carcinomaProc Eur Conf Clin Oncol, 4
M. Marinaccio, V. D’addario, A. Serratì, V. Pinto, G. Cagnazzo (1996)
Leuprolide acetate as a salvage-therapy in relapsed epithelial ovarian cancer.European journal of gynaecological oncology, 17 4
(1998)
A randomised trial of single agent carboplatin against a three-drug combination of CAP (cyclophosphamide, doxorubicin, cisplatin) in women with ovarian cancer. ICON collaborators. International Collaborative Ovarian Neoplasm StudyLancet, 352
Warren Ross, Tom Rowe, Bonnie Glisson, J. Yalowich, Leroy-Fong Liu (1984)
Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.Cancer research, 44 12 Pt 1
A. Hasenburg, A. Hasenburg, Tong Xw, Tong Xw, Dagmar-Christiane Fischer, Augusto Rojas-Martinez, C. Nyberg-Hoffman, Alan Kaplan, Raymond Kaufman, Ibrahim Ramzy, Estuardo Aguilar-Cordova, D. Kieback, D. Kieback (2001)
Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up.Gynecologic oncology, 83 3
G. Bolis, o. G. Scarf, A. Villa (1996)
A randomised study in recurrent ovarian cancer comparing the efficacy of single agent versus combination chemotherapy, according to time of relapse [abstract]Proc Am Soc Clin Oncol, 15
M. Markman, B. Reichman, T. Hakes, W. Jones, J. Lewis, S. Rubin, L. Almadrones, W. Hoskins (1991)
Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 9 10
I. Vergote, A. Himmelmann, B. Frankendal, M. Scheistrøen, K. Vlachos, C. Tropé (1992)
Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer.Gynecologic Oncology, 47
A. Athanassiou, D. Pectasides, I. Varthalitis (1994)
Taxol patients with cis/carbo platin-refractory ovarian carcinoma [abstract]Proc Am Soc Clin Oncol, 13
M. Bookman (1998)
Biological therapy of ovarian cancer: current directions.Seminars in oncology, 25 3
M. Marzola, M. Zucchetti, N. Colombo, C. Sessa, O. Pagani, M. D’Incalci, F. Cavalli, C. Mangioni (1993)
Low-dose oral etoposide in epithelial cancer of the ovary.Annals of oncology : official journal of the European Society for Medical Oncology, 4 6
D. Miller, M. Brady, R. Barrett (1992)
A Phase II Trial of Leuprolide Acetate in Patients with Advanced Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group StudyAmerican Journal of Clinical Oncology, 15
A. Gabizon, Y. Barenholz, M. Bialer (1993)
Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and DogsPharmaceutical Research, 10
P. Chollet, M. Bensmaïne, S. Brienza, C. Deloche, H. Curé, H. Caillet, E. Cvitkovic (1996)
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 7 10
G. Blackledge, F. Lawton, C. Redman, K. Kelly (1989)
Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.British Journal of Cancer, 59
M. Markman, E. Rowinsky, T. Hakes, B. Reichman, W. Jones, J. Lewis, S. Rubin, J. Curtin, R. Barakat, M. Phillips (1992)
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 9
M. Gore, V. Lévy, G. Rustin, T. Perren, A. Calvert, H. Earl, J. Thompson (1995)
Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.British Journal of Cancer, 72
M. Piccart, J. Green, Á. Lacave, N. Reed, I. Vergote, P. Benedetti‐Panici, A. Bonetti, V. Kristeller-Tome, C. Fernández, D. Curran, M. Glabbeke, D. Lacombe, M. Pinel, S. Pecorelli (2000)
Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 6
J.J. Kavanagh, R. Winn, M. Steger (1999)
Docetaxel for patients with ovarian cancer refractory to paclitaxel, an update [abstract]Proc Am Soc Clin Oncol, 18
K. Tewey, T. Rowe, L. Yang, B. Halligan, Leroy Liu (1984)
Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II.Science, 226 4673
R. Burger, P. Disaia, J. Roberts, M. O'Rourke, D. Gershenson, H. Homesley, S. Lichtman, W. Barnes, D. Moore, B. Monk (1999)
Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer.Gynecologic oncology, 72 2
O. Rixe, W. Ortuzar, M. Alvarez (1996)
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines of the National Cancer Institute’s Anticancer Drug Screen PanelBiochem Pharmacol, 52
E.J. Shpall, R.B. Jones, S.I. Bearman (1994)
Future strategies for the treatment of advanced EOC using high dose chemotherapy and autologous bone marrow supportGynecol Oncol, 54
R. Wit, M. Burg, A. Gaast, A. Logmans, G. Stoter, J. Verweij (1994)
Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.Annals of oncology : official journal of the European Society for Medical Oncology, 5 7
L. Levin, W. Hryniuk (1987)
Dose intensity analysis of chemotherapy regimens in ovarian carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 5 5
P. Hurteloup, P. Cappelaere, J. Armand, G. Mathé (1983)
Phase II clinical evaluation of 4'-epi-doxorubicin.Cancer treatment reports, 67 4
M.C. Locatelli, A. D’Antona, M. Vinci (1990)
Second-line chemotherapy with epirubicin (EDR) in ovarian carcinoma [abstract]Ann Oncol, 1
S. Cros, M. Wright, M. Morimoto, H. Lataste, Couzinier Jp, A. Krikorian (1989)
Experimental antitumor activity of Navelbine.Seminars in oncology, 16 2 Suppl 4
E. Bajetta, A. Leo, L. Biganzoli, L. Mariani, F. Cappuzzo, M. Bartolomeo, N. Zilembo, S. Artale, E. Magnani, L. Celio, R. Buzzoni, C. Carnaghi (1996)
Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 9
M. Markman, B. Bundy, D. Alberts, J. Fowler, D. Clark-Pearson, L. Carson, S. Wadler, Joshua Sickel (2001)
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology GrJournal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 4
J. Ahlgren, N. Ellison, R. Gottlieb, F. Laluna, J. Lokich, P. Sinclair, W. Ueno, G. Wampler, K. Yeung, D. Alt (1993)
Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 10
M. Kaufmann, T. Bauknecht, W. Jonat (1995)
Gemcitabine (GEM) in cisplatin-resistant ovarian cancer [abstract]Proc Am Soc Clin Oncol, 14
T. Eisen, T. Eisen, Chris Boshoff, C. Boshoff, I. Mak, Francisco Sapunar, M. Vaughan, L. Pyle, S.R.D. Johnston, R. A’Hern, I. Smith, M. Gore (2000)
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancerBritish Journal of Cancer, 82
A. Kudelka, D. Tresukosol, C. Edwards, R. Freedman, C. Levenback, P. Chantarawiroj, C. León, Edmund Kim, T. Madden, B. Wallin, M. Hord, C. Verschraegen, M. Raber, J. Kavanagh (1996)
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 5
D.H. Moore, F. Valea, L.S. Crumpler (1993)
Hexamethylmelamine/altretamine as second-line agent therapy for epithelial ovarian cancerGynecol Oncol, 51
R. Cersosimo, W. Hong (1986)
Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 4 3
F. Guéritte-Voegelein, D. Guénard, François Lavelle, Marie Goff, L. Mangatal, Pierre Potier (1991)
Relationships between the structure of taxol analogues and their antimitotic activity.Journal of medicinal chemistry, 34 3
E Trimble, J Adams, D. Vena, M Hawkins, M Friedman, J. Fisherman, M Christian, R. Canetta, N. Onetto, R. Hayn (1993)
Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 12
R. Coleman, K. Towlson, E. Wiltshaw, M. Slevin, P. Blake, R. Stein, R. Coombes, P. Harper (1990)
Epirubicin for pretreated advanced ovarian cancer.European journal of cancer, 26 7
O. Rixe, Waldo Ortuzar, M. Álvarez, R. Parker, E. Reed, K. Paull, T. Fojo (1996)
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.Biochemical pharmacology, 52 12
J. Malfetano, J. Beecham, B. Bundy, K. Hatch (1993)
A Phase II Trial of Medroxyprogesterone Acetate in Epithelial Ovarian Cancers: A Gynecologic Oncology Group StudyAmerican Journal of Clinical Oncology, 16
Victoria Seewaldt, Benjamin Greer, Joanna Cain, D. Figge, H. Tamimi, Wendy Brown, Sheree Miller (1994)
Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial.American journal of obstetrics and gynecology, 170 6
N. Abramson, P. Stokes (2001)
Ovarian and peritoneal papillary-serous carcinoma: pilot study using thalidomide [abstract]Proc Am Soc Clin Oncol, 20
J. Hamerlynck, A. Maskens, C. Mangioni, M. Burg, J. Wils, J. Vermorken, N. Rotmensz (1985)
Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study.Gynecologic oncology, 22 3
G. Minckwitz, Thomas Bauknecht, C. Visseren-Grul, J. Neijt (1999)
Phase II study of gemcitabine in ovarian cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 10 7
U. Wagner, S. Köhler, S. Reinartz, P. Giffels, J. Huober, K. Renke, H. Schlebusch, H. Biersack, V. Möbus, R. Kreienberg, T. Bauknecht, Dieter Krebs, D. Wallwiener (2001)
Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. CanClinical cancer research : an official journal of the American Association for Cancer Research, 7 5
D. Slamon, B. Leyland-Jones, S. Shark (1998)
Addition of herceptin to first line chemotherapy for HER-2 overexpressing metastatic breast cancer markedly increases anticancer activity a randomised controlled phase III trial [abstract]Proc Am Soc Clin Oncol, 17
P. Rose, J. Blessing, A. Mayer, H. Homesley (1998)
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 2
A. Gordon, J. Fleagle, D. Guthrie, D. Parkin, M. Gore, Á. Lacave (2001)
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 14
E. Eisenhauer, W. Huinink, K. Swenerton, L. Gianni, J. Myles, M. Burg, I. Kerr, J. Vermorken, K. Buser, N. Colombo, M. Bacon, Pedro Santabárbara, N. Onetto, B. Winograd, R. Canetta (1994)
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 12
J.J. Kavanagh, A.P. Kudelka, C.L. Edwards (1993)
A randomised crossover trial of parenteral hydoxyurea vs. high dose taxol in cisplatin/carboplatin resistant epithelial ovarian cancer [abstract]Proc Am Soc Clin Oncol, 12
E. Eisenhauer, J. Vermorken, M. Glabbeke (1997)
Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments].Annals of oncology : official journal of the European Society for Medical Oncology, 8 10
P. Bougnoux, V. Dieras, T. Petit (1999)
A multicenter phase II study of oxaliplatin (OXA) as a single agent in platinum (PT) or taxanes (TX) pretreated advanced ovarian cancer (AOC): final results [abstract]Proc Am Soc Clin Oncol, 18
S. Righetti, Gabriella Della, Torre, S. Pilotti, S. Mã©nard, Francesca Ottone, M. Colnaghi, M. Pierotti, Cinzialavarino, Mariagraziacornarotti, Silvia Sarooriana, Gian Bã, Giambattista Bresciani, Franco Spatti, Zunino (1996)
A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.Cancer research, 56 4
C. Mangioni, S. Franceschi, C. Vecchia, M. D’Incalci (1981)
High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy.Gynecologic oncology, 12 3
A. Gordon, C. Granai, P. Rose, J. Hainsworth, A. López, C. Weissman, Rosemary Rosales, Timothy Sharpington (2000)
Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 17
Y. Hsiang, Leroy Liu (1988)
Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin.Cancer research, 48 7
F. Hansen, I. Malthe, H. Krog (1990)
Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer.Gynecologic oncology, 36 3
H. Hirte, I. Vergote, J. Jeffrey, N. Grimshaw, G. Stuart, C. Mendiola, D. Vrobiof, M. Carey, S. Coppieters, B. Schwartz, D. Tu, A. Sadura, L. Seymour (2001)
An international multicentre Phase III study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/Paclitaxel + Platinum containing chemotherapy (CT), 20
N. Abramson, P. Stokes, Mathew Luke, A. Marks, Jeffrey Harris (2002)
Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 4
D.R. Shirey, J. J. Kavanagh, D.M. Gershenson (1987)
Tamoxifen therapy of epithelial ovarian cancerObstet Gynecol, 27
H. Andersson, K. Boman, M. Ridderheim (2000)
An updated analysis of a randomised study of single agent paclitaxel (P) given weekly or every 3 weeks to patients (pts) with ovarian cancer (ov) treated with prior platinum therapy [abstract]Proc Am Soc Clin Oncol, 19
M. Coenen, P. Berteloot, F. Amant, M. Gramberen, I. Vergote (2000)
Gemcitabine in Platin-Paclitaxel Resistant Ovarian Carcinoma, 19
J.B. Vermorken, A. Kobierska, B. Chevallier (2000)
A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin: EORTC Gynecological Cancer Cooperative GroupAnn Oncol, 11
David Silver, Piver Ms (1999)
Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum.American journal of clinical oncology, 22 5
D. Moore, F. Valea, L. Crumpler, W. Fowler (1993)
Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma.Gynecologic oncology, 51 1
D. Armstrong, E. Rowinsky, R. Donehower (1995)
A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer [abstract]Proc Am Soc Clin Oncol, 14
Elizabeth Swisher, D. Mutch, Janet Rader, A. Elbendary, Thomas Herzog (1997)
Topotecan in platinum- and paclitaxel-resistant ovarian cancer.Gynecologic oncology, 66 3
J. Vermorken, A. Kobierska, B. Chevallier, F. Zanaboni, A. Pawinski, G. Bolis (2000)
A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatinAnnals of Oncology, 11
R. D'Amato, M. Loughnan, E. Flynn, J. Folkman (1994)
Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences of the United States of America, 91 9
P Hoskins, K. Swenerton (1994)
Oral etoposide is active against platinum-resistant epithelial ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 1
A. Gadducci, F. Carnino, S. Chiara, I. Brunetti, L. Tanganelli, A. Romanini, M. Bruzzone, P. Conte (2000)
Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.Gynecologic oncology, 76 2
M. Bookman, H. Malmström, G. Bolis, A. Gordon, A. Lissoni, J. Krebs, S. Fields (1998)
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 10
S. Weiner, D. Alberts, E. Surwit, J. Davis, D. Grosso (1987)
Tamoxifen therapy in recurrent epithelial ovarian carcinoma.Gynecologic oncology, 27 2
J. Kavanagh, W. Roberts, P. Townsend, S. Hewitt (1989)
Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 7 1
M. Markman, T. Hakes, B. Reichman (1993)
Memorial Sloan Kettering experience with National Cancer Institute treatment referral center protocol 9103: taxol in refractory ovarian cancer [abstract]Proc Am Soc Clin Oncol, 12
U. Wagner, S. Kohler, S. Reinartz (2001)
Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody acal25: immune responses and survival in palliative treatmentClin Cancer Res, 7
ME Gore, I. Fryatt, E. Wiltshaw, T. Dawson, BA Robinson, AH Calvert (1989)
Cisplatin/carboplatin cross-resistance in ovarian cancer.British Journal of Cancer, 60
A. Manetta, K. Tewari, E. Podczaski (1997)
Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature.Gynecologic oncology, 66 1
M. Piccart, M. Gore, W. Huinink, A. Oosterom, J. Verweij, J. Wanders, Hilary Frankli, M. Bayssas, S. Kaye (1995)
Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer.Journal of the National Cancer Institute, 87 9
C. Doyle, M. Crump, M. Pintilie, A. Oza (2001)
Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 5
M. Markman, T. Hakes, R. Barakat, J. Curtin, L. Almadrones, W. Hoskins (1996)
Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 3
Daniel Shirey, D. Gershenson, R. Freedman, L. Copeland, L. Jones (1985)
Tamoxifen therapy of epithelial ovarian cancerInternational Journal of Gynecology & Obstetrics, 24
K. Wiman (1998)
New p53-based anti-cancer therapeutic strategiesMedical Oncology, 15
P. Hoskins, E. Eisenhauer, S. Beare, M. Roy, P. Drouin, G. Stuart, P. Bryson, R. Grimshaw, V. Capstick, B. Zee (1998)
Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 6
B. Uziely, S. Groshen, S. Jeffers, M. Morris, C. Russell, L. Roman, L. Muderspach, F. Muggia (1994)
Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications.Annals of oncology : official journal of the European Society for Medical Oncology, 5 9
A. Manetta, C. MacNeill, J.A. Lyter (1990)
Hexamethylmelamine as a single secondline agent in ovarian cancerGynecol Oncol, 36
M. Coenen, P. Berteloot, F. Amant (2000)
Gemcitabine in platin-paclitaxel resistant ovarian carcinoma [abstract]Proc Am Soc Clin Oncol, 19
J.B. Vermorken, M. Gore, T. Perren (2001)
Multicenter randomised phase II study of Oxaliplatin (OXA) or topotecan (TOPO) in platinum-pretreated epithelial ovarian cancer (EOC) patients (Pts) [abstract]Proc Am Soc Clin Oncol, 20
R. Pietras, B. Fendly, V. Chazin, M. Pegram, S. Howell, D. Slamon (1994)
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.Oncogene, 9 7
Valerie Israel, Augustin Garcia, Linda Roman, L. Muderspach, A. Burnett, S. Jeffers, F. Muggia (2000)
Phase II study of liposomal doxorubicin in advanced gynecologic cancers.Gynecologic oncology, 78 2
Volker Heinemann, L. Hertel, G. Grindey, W. Plunkett (1988)
Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.Cancer research, 48 14
Michael Friedlander, Michael Millward, D. Bell, R. Bugat, Paul Harnett, J. Moreno, L. Campbell, C. Varette, V. Ripoche, L. Kayitalire (1998)
A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 9 12
Elise Kohn, G. Sarosy, A. Bicher, Charles Link, M Christian, S. Steinberg, M. Rothenberg, D. Adamo, P. Davis, F. Ognibene, Robert Cunnion, Eddie Reed (1994)
Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.Journal of the National Cancer Institute, 86 1
Prudence Francis, J. Schneider, L. Hann, C. Balmaceda, Richard Barakat, M. Phillips, T. Hakes (1994)
Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 11
M. Markman, B.N. Bundy, D.S. Alberts (2001)
Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian cancer: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology GroupJ Clin Oncol, 19
A. Berchuck, M. Kohler, J. Marks, R. Wiseman, J. Boyd, R. Bast (1994)
The p53 tumor suppressor gene frequently is altered in gynecologic cancers.American Journal of Obstetrics and Gynecology, 170
E. Shpall, R. Jones, S. Bearman, M. Purdy (1994)
Future strategies for the treatment of advanced epithelial ovarian cancer using high-dose chemotherapy and autologous bone marrow support.Gynecologic oncology, 54 3
M. Gore, G. Rustin, H. Calvert (2002)
A multicentre, randomised, phase III study of topotecan (T) administered intravenously or orally for advanced epithelial ovarian carcinomaEur J Cancer, 38
Epithelial ovarian cancer (EOC) is the most common cause of death from gynecological malignancy in the industrialized world. Most patients present with advanced disease and, despite optimal surgical debulking and front-line chemotherapy with platinum- and taxane-based regimens, the majority will relapse. Relapsed EOC is incurable but there are various palliative treatment options. Patients who relapse more than 12 months after primary treatment have a good chance of response to re-challenge with platinum-based chemotherapy. Disease bulk, number of sites of disease, serous histology, type of chemotherapy, baseline hemoglobin, performance status, response to last chemotherapy, and presence of liver metastases also predict treatment outcome in relapsed disease.
American Journal of Cancer – Springer Journals
Published: Aug 9, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.